Increasing in demand for biologic therapeutics to treat cancer and autoimmune disorders is believed to be one of the major contributing factor for the high adoption of recombinant proteins during the forecast period. The key products of the cell line development industry refers blood factors, anti-body related molecules, enzymes, hormones, and monoclonal antibodies. Globally, there are more than 650 protein therapeutics out of which 400 products are approved globally.